07D10802-F79E-495E-B842-895C444CA439
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 40.04599211563732
- age_years
- 49
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.539
- G2M_CHECKPOINT+0.494
- E2F_TARGETS+0.466
- ANDROGEN_RESPONSE+0.461
- PROTEIN_SECRETION+0.419
- MYC_TARGETS_V2+0.394
- MITOTIC_SPINDLE+0.386
- TGF_BETA_SIGNALING+0.372
- UNFOLDED_PROTEIN_RESPONSE+0.343
- DNA_REPAIR+0.337
Top 10 suppressed
- KRAS_SIGNALING_DN-0.357
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.223
- COAGULATION-0.214
- MYOGENESIS-0.188
- APICAL_SURFACE-0.183
- INFLAMMATORY_RESPONSE-0.166
- ALLOGRAFT_REJECTION-0.137
- INTERFERON_ALPHA_RESPONSE-0.131
- SPERMATOGENESIS-0.129
- INTERFERON_GAMMA_RESPONSE-0.118
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6990AABF-A5F4-4784-91FF-286A0EE6A618 | — | — | 0.916 |
| 2 | 28B7B2FC-8270-42E3-95ED-4CC4F0979EE9 | — | — | 0.908 |
| 3 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.898 |
| 4 | 5EDF36F3-D370-4907-BDA1-8D5FD2B80513 | — | — | 0.895 |
| 5 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.884 |
| 6 | 431CF176-101C-482F-B2A4-617ADF6475A8 | — | — | 0.883 |
| 7 | SRR934777 | — | — | 0.882 |
| 8 | 8E898165-F557-4D73-9D67-ED735BE256B2 | — | — | 0.881 |
| 9 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.879 |
| 10 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.539 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.494 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.466 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.461 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.419 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.394 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.386 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.372 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.343 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.337 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.301 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.231 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.207 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.197 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.195 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.184 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.129 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.121 | Inavolisib | — uncovered |